Division of Bausch Health Companies Inc.
Latest From VitalScience Corp.
Q3 2012 biopharma financing, at just over $3 billion, showed a 13% increase over Q2. Follow-on public offerings again were the most prevalent financing type, accounting for a third of these dollars. M&A volume was down to just over $7 billion, compared with Q2’s $35.9 billion and only two Q3 transactions topped the billion-dollar mark. Antibody alliances made up just over a quarter of the total $2.2 billion in deal volume, with 19 deals signed in the area.
Highlights from the Q2 2010 review of pharmaceutical and biotechnology dealmaking: Biopharma companies raised a total of $3.4bn through 96 financings. Twenty-one acquisitions together reached $20.2bn, thanks to five deals each exceeding $3 billion - in aggregate accounting for 91% of the M&A total. The alliance volume was up to 115 transactions for a total of $2.8 billion in pre-commercialization money, with seven deals surpassing the $100 million mark.
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
- OTC, Consumer
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Bausch Health Companies Inc.
- Senior Management
- Contact Info
Phone: (905) 264-9697
93 Woodstream Blvd.
Woodbridge, L4L 7Y7
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.